Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals and ADC Therapeutics, has made significant progress with ZYNLONTA® (loncastuximab tesirine-lpyl) in China.
The China National Medical Products Administration (NMPA) has accepted the Biologics Licence Application (BLA) for ZYNLONTA®, which is seeking approval for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy in China.
ZYNLONTA® has already been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The approved indications include DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.
The application was made based on the positive results from OL-ADCT-402-001, a Phase 2 bridging clinical trial for ZYNLONTA® in Chinese patients with r/r DLBCL. This study was designed to assess the efficacy and safety of ZYNLONTA® as a single-agent treatment for these patients.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!